Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131353) titled 'Phase III Clinical Trial of BXOS110 for the Treatment of Acute Ischemic Stroke' on Sept. 1.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
AIS(acute ischaemic stroke)
Intervention:
BXOS110 experimental group (3.0 mg/kg, maximum =300 mg):BXOS110
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-09-01
Target Sample Size: BXOS110 experimental group (3.0 mg/kg, maximum =300 mg):556;placebo group:556;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj....